Pfizer Ltd.

Despite a broadly positive market environment, Pfizer Ltd. has fallen to a fresh 52-week low of Rs 4,045.7 on 15 Sep 2026, marking a decline of over 27% from its 52-week high of Rs 5,561.55. This drop comes after six consecutive sessions of losses, signalling persistent selling pressure on the stock even as the Sensex trades near its own 52-week lows.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 September 2026, providing investors with the latest insights into the company’s performance and outlook.

For the sixth consecutive session, Pfizer Ltd. has closed lower, culminating in a fresh 52-week low of Rs 4,054.55 on 11 Sep 2026. This marks a 12.08% decline over the past six days, extending the stock’s underperformance amid a broader market that itself is struggling but not to the same extent.

Pfizer Ltd. has reached a new 52-week low price of Rs.4118.05 on 10 September 2026, marking a significant decline amid a series of consecutive losses and underperformance relative to its sector and broader market indices.

For the fifth straight session, Pfizer Ltd. closed lower, breaching its 52-week low at Rs 4,178.05 on 09 Sep 2026, marking a cumulative decline of 8.75% over this period amid broader market weakness.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating technical parameters and underwhelming returns relative to the Sensex, paints a challenging outlook for investors as of early September 2026.

Pfizer Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a "very expensive" to an "expensive" rating. This change reflects a recalibration of price attractiveness amid recent market volatility and sector-wide pressures, with key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a less compelling entry point for investors.

Pfizer Ltd. has declined to a fresh 52-week low of Rs 4,334 on 8 September 2026, marking a significant downturn for the pharmaceutical company as it underperforms its sector and broader market indices amid a challenging market environment.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 31 August 2026. This revision reflects a combination of deteriorating technical indicators, subdued long-term financial growth, and valuation concerns despite recent positive quarterly results. The company’s current Mojo Score stands at 48.0, with a Sell grade, signalling caution for investors amid mixed signals across quality, valuation, financial trends, and technical analysis.

Pfizer Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 29 August 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent downgrade in daily moving averages and a 2.49% decline in the latest session, several weekly and monthly technical indicators present a complex picture, signalling both bullish and bearish tendencies. This article analyses the latest technical parameters, price momentum, and comparative returns to provide a comprehensive view of Pfizer’s current market positioning.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive tilt, the stock’s overall technical indicators present a nuanced picture, with mixed signals from key oscillators and moving averages, prompting a recent downgrade in its Mojo Grade from Hold to Sell.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a 2.48% gain on 20 Aug 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators, challenging investors to carefully analyse the evolving price dynamics.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 Aug 2026. This shift reflects a combination of deteriorating technical indicators, subdued long-term financial growth, and valuation concerns despite recent positive quarterly results. The company’s current Mojo Score stands at 48.0, with a small-cap market cap grade, signalling caution for investors amid mixed performance metrics.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle but notable shift in its technical momentum, moving from a mildly bullish stance to a mildly bearish outlook. This change is reflected across key technical indicators including MACD, RSI, moving averages, and other momentum oscillators, signalling a cautious phase for investors amid mixed market signals and recent price movements.

Pfizer Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced outlook for the pharmaceutical small-cap amid broader market fluctuations.